Video Insights
Advertisement
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.